Shanghai Universal Biotech Co.,Ltd. (SHE:301166)
China · Delayed Price · Currency is CNY 29.40
+0.13 (0.44%)
Sep 1, 2026, 4:00 PM EDT
SHE:301166 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,147 | 1,084 | 1,118 | 1,226 | 1,195 | 1,110 |
| 1,147 | 1,084 | 1,118 | 1,226 | 1,195 | 1,110 | |
Revenue Growth | 7.23% | -3.05% | -8.82% | 2.57% | 7.70% | 30.69% |
Cost of Revenue | 921.02 | 882.82 | 916.48 | 995.73 | 930.56 | 852.59 |
Gross Profit | 226.4 | 200.89 | 201.28 | 230.1 | 264.56 | 257.08 |
Selling, General & Admin | 196.67 | 182.54 | 167.86 | 173.8 | 134.14 | 109.06 |
Research & Development | 74.51 | 65.83 | 61.31 | 56.62 | 32.14 | 16.31 |
Other Operating Expenses | 6.63 | 3.99 | 3.88 | 2.15 | 1.25 | 3.38 |
Operating Expenses | 287.86 | 262.41 | 239.19 | 236.31 | 178.74 | 131.75 |
Operating Income | -61.46 | -61.52 | -37.91 | -6.21 | 85.82 | 125.33 |
Interest Expense | -0.9 | -0.9 | -1.04 | -2.06 | -1.29 | -0.11 |
Interest & Investment Income | 11.89 | 13.52 | 23.74 | 24.99 | 27.11 | 3.53 |
Currency Exchange Gain (Loss) | -1.4 | -1.4 | -2.11 | -3.24 | -2.83 | 0.22 |
Other Non Operating Income (Expenses) | -2.79 | -0.5 | -0.29 | -0.47 | -0.52 | -0.36 |
EBT Excluding Unusual Items | -54.65 | -50.8 | -17.61 | 13.01 | 108.29 | 128.61 |
Gain (Loss) on Sale of Investments | 10.15 | 11.22 | 13.91 | 15.24 | 14.5 | - |
Gain (Loss) on Sale of Assets | -0.04 | -0.68 | -1.24 | -0 | 0.01 | -0.24 |
Asset Writedown | 0.43 | - | -0 | -0 | - | - |
Other Unusual Items | 6.6 | 6.6 | 5.76 | 7.24 | 5.72 | 9.29 |
Pretax Income | -37.51 | -33.67 | 0.82 | 35.48 | 128.52 | 137.65 |
Income Tax Expense | -16.15 | -10.72 | -9.33 | -4.84 | 21.92 | 28.93 |
Net Income | -21.36 | -22.95 | 10.15 | 40.32 | 106.6 | 108.73 |
Net Income to Common | -21.36 | -22.95 | 10.15 | 40.32 | 106.6 | 108.73 |
Net Income Growth | - | - | -74.83% | -62.18% | -1.96% | 42.15% |
Shares Outstanding (Basic) | 86 | 88 | 85 | 86 | 87 | 65 |
Shares Outstanding (Diluted) | 86 | 88 | 85 | 86 | 87 | 65 |
Shares Change | 1.20% | 4.36% | -1.41% | -1.02% | 32.32% | 1.05% |
EPS (Basic) | -0.25 | -0.26 | 0.12 | 0.47 | 1.23 | 1.66 |
EPS (Diluted) | -0.25 | -0.26 | 0.12 | 0.47 | 1.23 | 1.66 |
EPS Growth | - | - | -74.47% | -61.79% | -25.90% | 40.68% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | -133.45 | -43.62 | 4.77 | -85.87 | -204.8 | 44.72 |
Free Cash Flow Per Share | -1.55 | -0.49 | 0.06 | -1.00 | -2.36 | 0.68 |
Dividend Per Share | 0.600 | 0.600 | 0.230 | 0.470 | 0.900 | 0.500 |
Dividend Growth | 160.87% | 160.87% | -51.06% | -47.78% | 80.00% | - |
Gross Margin | 19.73% | 18.54% | 18.01% | 18.77% | 22.14% | 23.17% |
Operating Margin | -5.36% | -5.68% | -3.39% | -0.51% | 7.18% | 11.29% |
Profit Margin | -1.86% | -2.12% | 0.91% | 3.29% | 8.92% | 9.80% |
Free Cash Flow Margin | -11.63% | -4.03% | 0.43% | -7.00% | -17.14% | 4.03% |
EBITDA | -43.87 | -44.4 | -22.96 | 4.39 | 92.32 | 130.52 |
EBITDA Margin | -3.82% | -4.10% | -2.05% | 0.36% | 7.72% | 11.76% |
D&A For EBITDA | 17.59 | 17.12 | 14.95 | 10.6 | 6.5 | 5.19 |
EBIT | -61.46 | -61.52 | -37.91 | -6.21 | 85.82 | 125.33 |
EBIT Margin | -5.36% | -5.68% | -3.39% | -0.51% | 7.18% | 11.29% |
Effective Tax Rate | - | - | - | - | 17.05% | 21.01% |
Revenue as Reported | 1,084 | 1,084 | 1,118 | 1,226 | 1,195 | 1,110 |
Advertising Expenses | - | 4.82 | 4.05 | 9.56 | 5.81 | 5.08 |